Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
13.44
+0.30 (2.28%)
Aug 10, 2026, 1:22 PM EDT - Market open
Alpha Tau Medical Employees
Alpha Tau Medical had 121 employees as of December 31, 2025. The number of employees decreased by 4 or -3.20% compared to the previous year.
Employees
121
Change (1Y)
-4
Growth (1Y)
-3.20%
Revenue / Employee
n/a
Profits / Employee
-$470,041
Market Cap
1.21B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 121 | -4 | -3.20% |
| Dec 31, 2024 | 125 | 4 | 3.31% |
| Dec 31, 2023 | 121 | 27 | 28.72% |
| Dec 31, 2022 | 94 | 11 | 13.25% |
| Dec 31, 2021 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Wave Life Sciences | 317 |
| EyePoint | 214 |
| Cullinan Therapeutics | 109 |
| Lexicon Pharmaceuticals | 81 |
| Inventiva | 77 |
| Alto Neuroscience | 68 |
| Seaport Therapeutics | 58 |
DRTS News
- 20 days ago - Alpha Tau reports Alpha DaRT combination study results - TheFly
- 20 days ago - Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success - GlobeNewsWire
- 26 days ago - Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer - TheFly
- 26 days ago - Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center - GlobeNewsWire
- 6 weeks ago - Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT - TheFly
- 6 weeks ago - Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel - GlobeNewsWire
- 2 months ago - Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial - TheFly
- 2 months ago - Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control - GlobeNewsWire